en · de · es · fr · pt
field-notes.peptides3626.com › Blog › Analytical Detection And Stability — Questions and Answers

Analytical Detection And Stability — Questions and Answers

By Editorial Desk · published 2026-07-25 · last reviewed 2026-08-01 · Blog

A practical reference on nuclear receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Analytical Detection and Stability

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Handling Storage and Quality Control

Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.

Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.

Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.

Sr9009 at a glance

PropertyValueNotes
Common synonymsSR9009; StenabolicNickname is not a chemical name.
Typical analytical methodLC-MS/MSOften with isotope-labeled internal standard.
Storage temperature-20 °CDesiccated and protected from light.
Solution stabilityDMSO stock; avoid freeze-thawStore at -20 to -80 °C.
Regulatory statusNot approved; varies by countryMay be restricted as research chemical.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

Related pages on this site

Reference notes

== Transcendental/reverse dependent origination == Understanding dependent origination is indispensable for realizing nirvana since it leads to insight into how the process of dependent arising can be brought to an end (i.e. nirvana). Since the process of dependent origination always produces suffering, the reversal or deactivation of the sequence is seen by Buddhists as the way to stop the entire process. Traditionally, the reversal of the sequence of the twelve nidanas is explained as leading to the cessation of rebirth and suffering. The early Buddhist texts state that on the arising of wisdom or insight into the true nature of things, dependent origination ceases. Some suttas state that "from the fading and cessation of ignorance without remainder comes the cessation of saṅkhāras..." et cetera (this is said to lead to the cessation of the entire twelve-fold chain in reverse order). According to Jayarava Attwood, while some dependent origination passages (termed lokiya, worldly) "[model] beings trapped in cycles of craving and grasping, birth and death", other passages (termed lokuttara, 'beyond the world') "[model] the process and dynamics of liberation from those same cycles." According to Bodhi, these are also classified as "exposition of the round" (vaṭṭakathā) and "the ending of the round" (vivaṭṭakathā). Beni Barua called these two different kinds of dependent origination "cyclic" and "progressive".

== Major branches == Modern neuroscience education and research activities can be very roughly categorized into the following major branches, based on the subject and scale of the system in examination as well as distinct experimental or curricular approaches. Individual neuroscientists, however, often work on questions that span several distinct subfields.

Announced on 8 May 2024, AlphaFold 3 was co-developed by Google DeepMind and Isomorphic Labs, both subsidiaries of Alphabet. AlphaFold 3 is not limited to proteins, as it can also predict the structures of protein complexes with DNA, RNA, post-translational modifications and selected ligands and ions. AlphaFold 3 introduces the "Pairformer," a deep learning architecture inspired by the transformer, which is considered similar to, but simpler than, the Evoformer used in AlphaFold 2. The Pairformer module's initial predictions are refined by a diffusion model. This model begins with a cloud of atoms and iteratively refines their positions, guided by the Pairformer's output, to generate a 3D representation of the molecular structure. The AlphaFold server was created to provide free access to AlphaFold 3 for non-commercial research. As of November 2025, the AlphaFold 3 research paper has been directly cited more than 9,000 times.

Isotope masses from: Wang, Meng; Huang, W.J.; Kondev, F.G.; Audi, G.; Naimi, S. (2021). "The AME 2020 atomic mass evaluation (II). Tables, graphs and references*". Chinese Physics C. 45 (3) 030003. doi:10.1088/1674-1137/abddaf. Isotopic compositions and standard atomic masses from: Kondev, F. G.; Wang, M.; Huang, W. J.; Naimi, S.; Audi, G. (2021). "The NUBASE2020 evaluation of nuclear properties" (PDF). Chinese Physics C. 45 (3) 030001. doi:10.1088/1674-1137/abddae. de Laeter, John Robert; Böhlke, John Karl; De Bièvre, Paul; Hidaka, Hiroshi; Peiser, H. Steffen; Rosman, Kevin J. R.; Taylor, Philip D. P. (2003). "Atomic weights of the elements. Review 2000 (IUPAC Technical Report)". Pure and Applied Chemistry. 75 (6): 683–800. doi:10.1351/pac200375060683. Wieser, Michael E. (2006). "Atomic weights of the elements 2005 (IUPAC Technical Report)". Pure and Applied Chemistry. 78 (11): 2051–2066. doi:10.1351/pac200678112051. "News & Notices: Standard Atomic Weights Revised". International Union of Pure and Applied Chemistry. 19 October 2005. Half-life, spin, and isomer data selected from the following sources. Kondev, F. G.; Wang, M.; Huang, W. J.; Naimi, S.; Audi, G. (2021). "The NUBASE2020 evaluation of nuclear properties" (PDF). Chinese Physics C. 45 (3) 030001. doi:10.1088/1674-1137/abddae. National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.

Sources: en.wikipedia.org

Notes from published material

== Structural studies == As of late 2007, 7 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1VLP​, PDB: 1YBE​, PDB: 1YIR​, PDB: 1YTD​, PDB: 1YTE​, PDB: 1YTK​, and PDB: 2F7F​.

== History == The use of cold for pain relief and as an anti-inflammatory has been known since the time of Hippocrates (460–377 BC). Since then there have been numerous accounts of ice used for pain relief, including from the Ancient Egyptians and Avicenna of Persia (982–1070 AD). In 1812, Napoleon's surgeon general noted that half-frozen soldiers from the Moscow battle were able to tolerate amputations with reduced pain. In 1851, ice and salt mixtures were promoted by Arnott for the treatment of nerve pain. Campbell White, in 1899, was the first to use refrigerants medically, and Allington, in 1950, was the first to use liquid nitrogen for medical treatments. In 1961, Cooper et al. created an early cryoprobe that reached −190 °C using liquid nitrogen. Shortly thereafter, in 1967, an ophthalmic surgeon named Amoils used carbon dioxide and nitrous oxide to create a cryoprobe that reached −70 °C.

The Philippine cobra (Naja philippinensis) is one of the most venomous cobra species in the world based on murine LD50 studies. The average subcutaneous LD50 for this species is 0.20 mg/kg. The lowest LD50 reported value for this snake is 0.14 mg/kg SC, while the highest is 0.48 mg/kg SC. and the average venom yield per bite is 90–100 mg. The venom of the Philippine cobra is a potent postsynaptic neurotoxin which affects respiratory function and can cause neurotoxicity and respiratory paralysis, as the neurotoxins interrupt the transmission of nerve signals by binding to the neuromuscular junctions near the muscles. Research has shown its venom is purely a neurotoxin, with no apparent necrotizing components and no cardiotoxins. These snakes are capable of accurately spitting their venom at a target up to 3 metres (9.8 ft) away. Bites from this species produce prominent neurotoxicity and are considered especially dangerous. A study of 39 patients envenomed by the Philippine cobra was conducted in 1988. Neurotoxicity occurred in 38 cases and was the predominant clinical feature. Complete respiratory failure developed in 19 patients, and was often rapid in onset; in three cases, apnea occurred within just 30 minutes of the bite. There were two deaths, both in patients who were moribund upon arrival at the hospital. Three patients developed necrosis, and 14 individuals with systemic symptoms had no local swelling at all. Both cardiotoxicity and reliable nonspecific signs of envenoming were absent.

== Sources == Bartusis, Mark C. (1997). The Late Byzantine Army: Arms and Society, 1204–1453. University of Pennsylvania Press. ISBN 0-8122-1620-2. Geanakoplos, Deno John (1959). Emperor Michael Palaeologus and the West, 1258–1282: A Study in Byzantine-Latin Relations. Cambridge, Massachusetts: Harvard University Press. Nicol, Donald M. (1993) [1972]. The Last Centuries of Byzantium, 1261–1453 (Second ed.). Cambridge: Cambridge University Press. ISBN 978-0-521-43991-6. Wolff, Robert Lee (1969) [1962]. "The Latin Empire of Constantinople, 1204–1261". In Setton, Kenneth M.; Wolff, Robert Lee; Hazard, Harry W. (eds.). A History of the Crusades, Volume II: The Later Crusades, 1189–1311. Vol. 2 (Second ed.). Madison, Milwaukee, and London: University of Wisconsin Press. pp. 186–233. ISBN 0-299-04844-6.

=== Mechanical bonding effects on non-covalent interactions === The strength of non-covalent interactions in a mechanically interlocked molecular architecture increases as compared to the non-mechanically bonded analogues. This increased strength is demonstrated by the necessity of harsher conditions to remove a metal template ion from catenanes as opposed to their non-mechanically bonded analogues. This effect is referred to as the "catenand effect". The augmented non-covalent interactions in interlocked systems compared to non-interlocked systems has found utility in the strong and selective binding of a range of charged species, enabling the development of interlocked systems for the extraction of a range of salts. This increase in strength of non-covalent interactions is attributed to the loss of degrees of freedom upon the formation of a mechanical bond. The increase in strength of non-covalent interactions is more pronounced on smaller interlocked systems, where more degrees of freedom are lost, as compared to larger mechanically interlocked systems where the change in degrees of freedom is lower. Therefore, if the ring in a rotaxane is made smaller the strength of non-covalent interactions increases, the same effect is observed if the thread is made smaller as well.

Sources: en.wikipedia.org

Frequently asked questions

How is SR9009 measured in samples?

The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.

What storage conditions are typical for SR9009?

Solid material is usually kept at -20 °C, desiccated, and protected from light. Dimethyl sulfoxide stocks should be stored cold and subjected to minimal freeze-thaw cycles. Aqueous solutions are generally less stable and should be prepared fresh when possible.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. It is not an approved medicine, and some places restrict or ban sales for human consumption. Buyers should verify local rules and product documentation before procurement.

How should SR9009 be stored?

Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.

Network